CPC C07K 14/64 (2013.01) [A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 9/14 (2018.01); A61P 13/12 (2018.01); A61K 38/00 (2013.01)] | 3 Claims |
1. A peptide having a formula:
Nter-Ac-L-E-G-R-E-K-V-R-A-X19-I-X21-X22-E-G-X25-S-T-F-S-X30-R-A-X33-NH2-Cter
wherein:
Nter represents the N-terminal end of the peptide;
Cter represents the C-terminal end of the peptide;
Ac represents acetyl group;
L represents leucine
E represents glutamic acid;
G represents glycine;
R represents arginine;
K represents lysine;
V represents valine;
A represents alanine;
X19 represents Nε-acetyl-lysine;
I represents isoleucine;
X21 represents 2-amino-isobutyric acid
X22 represents 2-amino-isobutyric acid;
X25 represents the following structure:
in which:
* represents a covalent bond with the glycine preceding X25 in the formula;
♦ represents a covalent bond with the serine following X25 in the formula; and
Z represents a group of:
-[(PEGxx)b(gE)cCd],
b represents 3;
c represents 3;
PEGxx represents a polyethylene glycol derivative TTDS;
gE represents gamma-glutamic acid; and
Cd represents a linear saturated C16 (Palmitoyl) acyl group;
S represents serine;
T represents threonine;
F represents phenylalanine;
X30 represents α-methyl-lysine;
and
X33 represents Nε-acetyl-lysine;
or a salt or solvate thereof.
|